QNTA - QNTA STOCK NEWS

Medolife Rx, a biotechnology company and majority-owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), has entered discussions with AsSeenOnTV.Pro to promote its AELIA and Immunapen products. The evaluation team from AsSeenOnTV.Pro reported positive reviews on the product's effectiveness and attractiveness, noting quick results for users and competitive pricing. CEO Dr. Arthur Mikaelian expressed optimism about reaching a wider audience through this partnership. The company thanks shareholders for their participation in a recent investor call and anticipates more positive updates soon.

Medolife Rx, a biotech firm under Quanta (QNTA), announced a conference call scheduled for May 12 to discuss key topics including potential investments, FDA applications for Escozine as a COVID-19 treatment, and company management changes. CEO Dr. Arthur Mikaelian aims to address shareholder concerns and provide updates on clinical strategies in the Dominican Republic and Mexico. The call will also cover new sales and marketing strategies and collaborative opportunities with pharmaceutical companies.

Medolife Rx, a subsidiary of Quanta (OTCQB: QNTA), is revamping its online marketing strategy, starting with a renewed focus on the AELIA brand wellness products. The current manager of marketing has mutually stepped down, as Medolife seeks a new director to lead these initiatives. The company aims to enhance product awareness and improve consumer engagement through updated websites and social media platforms. Medolife's CEO expresses optimism about the new direction, indicating plans for further positive developments.

Medolife Rx, a biopharmaceutical company and subsidiary of Quanta (OTCQB: QNTA), has submitted final clinical trial data to the Dominican Republic's Ministry of Health for approval of Escozine as a COVID-19 treatment. This follows a meeting with government officials, demonstrating the product's efficacy against SARS-CoV-2 variants. Medolife plans to engage with the US FDA for pilot study approval later this month to advance Escozine's development in the US market.

Quanta, Inc. (OTCQB: QNTA) subsidiary Medolife Rx presented its venom-to-drug project at a Dominican Republic conference focused on natural resource utilization. The drug, Escozine, aims to treat COVID-19 and is already registered as an alternative oncology medicine in the DR. The company anticipates receiving an export license by January and plans to export Escozine to Mexico. Additionally, discussions with the German ambassador were held to explore Escozine's potential as a COVID-19 treatment in Germany. Medolife's patented technology and commitment to local employment were highlighted during the event.

Medolife Rx, a biopharmaceutical subsidiary of Quanta, Inc. (OTCQB: QNTA), announced positive results from a study on its Aelia polarized CBD muscle rub. The study found that Aelia products are up to 604.7% stronger than non-polarized CBD muscle rubs in inhibiting the COX-2 enzyme linked to inflammation. This study, supervised by a third-party scientist, positions Aelia as a leader in topical pain relief. The company plans further research on the effectiveness of its polarization technology in various applications, including drug development.

Medolife Rx, a subsidiary of Quanta, Inc. (OTCQB: QNTA), has scheduled a conference call with investors on November 23, 2021. Key topics include a 257% increase in Ibuprofen efficacy, advances in CBD muscle rub studies, updates on government relations in the Dominican Republic, and various product distribution initiatives. CEO Dr. Mikaelian highlighted the importance of the third quarter and upcoming opportunities to expedite the growth of the Escozine product line. The call aims to provide transparency and address investor questions regarding recent company milestones and future plans.

Medolife Rx, a subsidiary of Quanta, Inc. (OTCQB: QNTA), announces upcoming commercials featuring Tony Hawk for its Aelia pain management products. The first ad will launch on social media this November, followed by a holiday-themed ad in December. Medolife showcases its products at events, aiming to educate consumers on its proprietary technology that enhances ingredient potency. The company is completing a pharmacokinetic study for its lead candidate, Escozine, and seeks approval for its name change. Medolife focuses on innovative clinical research and consumer wellness products.

Medolife Rx, a majority-owned subsidiary of Quanta, Inc. (OTCQB: QNTA), successfully uplisted from the OTC Pink Sheets to the OTCQB Venture Market. This uplisting is expected to enhance visibility among investors and facilitate access to larger investment opportunities due to improved reporting standards. Medolife is advancing its clinical programs, particularly the Escozine® drug candidate, and expanding its consumer product lines. The OTCQB Market is recognized by the SEC, offering transparency and credibility for investors.